Pfizer said on Wednesday booster doses of its COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses in people aged 65 and above in a late-stage study.
The study, initiated in May, tested the company’s next-generation pneumococcal conjugate vaccine, PREVNAR 20, with a third dose of the Pfizer-BioNTech COVID-19 shot in 570 participants.
The aim of the study was to test the safety of the combination and the immune response after adding the pneumonia vaccine to the existing COVID-19 vaccine.
The company said responses elicited by PREVNAR 20 and booster dose of the COVID-19 vaccine were similar when given together or with placebo.
The data provides evidence supporting the potential to administer PREVNAR 20 and the company’s COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies for recommended immunization, Pfizer said.
PREVNAR 20 was approved by the US Food and Drug Administration in June last year to help protect adults against most invasive pneumococcal diseases and pneumonia.
Study participants were recruited from the companies’ late-stage COVID-19 vaccine study, and those who had received the second dose of the company’s COVID-19 vaccine at least six months before entering the co-administration study.
US FDA backs Pfizer’s COVID-19 booster shot for 12- to 15-year-oldsThe US Food and Drug Administration on Monday authorized the use of a third dose of the Pfizer and BioNTech COVID-19 vaccine for children ages 12 to ... Coronavirus
Pfizer pill becomes first US-authorized home COVID-19 treatmentUS health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off ... Coronavirus
New Zealand links 26-year-old man’s death to Pfizer COVID-19 vaccineNew Zealand authorities on Monday said they had linked a 26-year-old man’s death to Pfizer Inc’s COVID-19 vaccine after the person suffered ... Coronavirus
GSK to test experimental drug to treat pneumonia from coronavirusGlaxoSmithKline will start trials of an experimental rheumatoid arthritis drug on patients suffering from pneumonia related to COVID-19 at the end of ... Coronavirus